Literature DB >> 8962608

[Incidence of point mutations in Ki-ras codon 12 and 13 in squamous epithelial carcinomas of the head-neck region].

I O Rathcke1, S Gottschlich, T Görögh, B M Lippert, J A Werner.   

Abstract

BACKGROUND: Point mutations of ras genes are one of the most frequent genetic alterations in human malignancies with up to over 95% in certain tumors. Some studies have presumed a low incidence of point mutations in Ki-ras gene codons 12 and 13 in squamous cell carcinoma of the head and neck (SCCHN). The objective of this study was to gain more information about the significance of point mutations in Ki-ras codons 12 and 13 by investigation of a high number of cases.
METHODS: By employing the polymerase chain reaction with specific primers, 63 fresh tumor biopsies were investigated by the nonradioisotopic single-strand conformation polymorphism (SSCP) analysis. To cooperate the efficiency and to characterize the nature of the point mutations, direct fluorescence-labeled DNA sequencing was performed in two cases.
RESULTS: Five out of the 63 (7.9%) SCCHN samples exhibited point mutations in codons 12 and 13 by SSCP analysis. In two out of these mutated cases, a G to T transversion in codon 12.2 of the Ki-ras gene was detected. The analysis of the patient's clinical parameters as well as the histopathological grading and tumor staging revealed no correlation with the Ki-ras point mutation.
CONCLUSIONS: Ki-ras point mutations in codons 12 and 13 are a rare event in SCCHN. These data give additional evidence that these genetic alterations do not play a major role in the development of malignancies of the upper aerodigestive tract.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8962608     DOI: 10.1055/s-2007-997616

Source DB:  PubMed          Journal:  Laryngorhinootologie        ISSN: 0935-8943            Impact factor:   1.057


  6 in total

Review 1.  Biomarkers of head and neck cancer, tools or a gordian knot?

Authors:  Evangeli S Lampri; Georgios Chondrogiannis; Elli Ioachim; Anna Varouktsi; Antigoni Mitselou; Aggeliki Galani; Evangelos Briassoulis; Panagiotis Kanavaros; Vasiliki Galani
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck.

Authors:  Francesco Perri; Francesco Longo; Franco Ionna; Francesco Caponigro
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

3.  TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression.

Authors:  Umamaheswar Duvvuri; Daniel J Shiwarski; Dong Xiao; Carol Bertrand; Xin Huang; Robert S Edinger; Jason R Rock; Brian D Harfe; Brian J Henson; Karl Kunzelmann; Rainer Schreiber; Raja S Seethala; Ann Marie Egloff; Xing Chen; Vivian W Lui; Jennifer R Grandis; Susanne M Gollin
Journal:  Cancer Res       Date:  2012-05-07       Impact factor: 12.701

4.  Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer.

Authors:  Malek B Hannouf; Chander Sehgal; Jeffrey Q Cao; Joseph D Mocanu; Eric Winquist; Gregory S Zaric
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

5.  Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck.

Authors:  Susumu Okano; Takayuki Yoshino; Masato Fujii; Yusuke Onozawa; Takeshi Kodaira; Hirofumi Fujii; Tetsuo Akimoto; Satoshi Ishikura; Masahiko Oguchi; Sadamoto Zenda; Barbara de Blas; Makoto Tahara; Frank Beier
Journal:  Jpn J Clin Oncol       Date:  2013-03-10       Impact factor: 3.019

6.  Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial.

Authors:  Takayuki Yoshino; Yasuhisa Hasegawa; Shunji Takahashi; Nobuya Monden; Akihiro Homma; Kenji Okami; Yusuke Onozawa; Masato Fujii; Takahide Taguchi; Barbara de Blas; Frank Beier; Makoto Tahara
Journal:  Jpn J Clin Oncol       Date:  2013-03-10       Impact factor: 3.019

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.